Works matching IS 19466234 AND DT 2012 AND VI 4 AND IP 148

Results: 5
    1

    Targeted Disruption of the BCL9/β-Catenin Complex Inhibits Oncogenic Wnt Signaling.

    Published in:
    Science Translational Medicine, 2012, v. 4, n. 148, p. 1, doi. 10.1126/scitranslmed.3003808
    By:
    • Takada, Kohichi;
    • Di Zhu;
    • Bird, Gregory H.;
    • Kumar, Sukhdeo;
    • Jian-Jun Zhao;
    • Mani, Mala;
    • Lemieux, Madeleine;
    • Carrasco, Daniel E.;
    • Ryan, Jeremy;
    • Horst, David;
    • Fulciniti, Mariateresa;
    • Munshi, Nikhil C.;
    • Wenqing Xu;
    • Kung, Andrew L.;
    • Shivdasani, Ramesh A.;
    • Walensky, Loren D.;
    • Carrasco, Daniel Ruben
    Publication type:
    Article
    2

    Engineering Approaches to Immunotherapy.

    Published in:
    Science Translational Medicine, 2012, v. 4, n. 148, p. 1, doi. 10.1126/scitranslmed.3003763
    By:
    • Swartz, Melody A.;
    • Hirosue, Sachiko;
    • Hubbell, Jeffrey A.
    Publication type:
    Article
    3
    4
    5

    Niacin Lipid Efficacy Is Independent of Both the Niacin Receptor GPR109A and Free Fatty Acid Suppression.

    Published in:
    Science Translational Medicine, 2012, v. 4, n. 148, p. 1, doi. 10.1126/scitranslmed.3003877
    By:
    • Lauring, Brett;
    • Taggart, Andrew K. P.;
    • Tata, James R.;
    • Dunbar, Richard;
    • Caro, Luzelena;
    • Kang Cheng;
    • Jayne Chin;
    • Colletti, Steven L.;
    • Cote, Josee;
    • Khalilieh, Sauzanne;
    • Jiajun Liu;
    • Wen-Lin Luo;
    • MacLean, Alexandra A.;
    • Peterson, Laurence B.;
    • Polis, Adam B.;
    • Sirah, Waheeda;
    • Tsuei-Ju Wu;
    • Xuan Liu;
    • Lan Jin;
    • Kenneth Wu
    Publication type:
    Article